Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors

Background: Pituitary Adenoma, a neoplastic proliferation of anterior pituitary hormone producing cells, is mainly considered benign but some are clinically aggressive and recurrent and very rarely malignant. From recent advances in pathological and molecular study, there is a continuous search for...

Full description

Saved in:
Bibliographic Details
Main Authors: Chhanda Das, Madhumita Mukhopadhyay, Satinath Mukhopadhyay, Avijit Hazra
Format: Article
Language:English
Published: Association of Clinical Pathologists of Nepal 2023-12-01
Series:Journal of Pathology of Nepal
Subjects:
Online Access:https://www.nepjol.info/index.php/JPN/article/view/51016
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849230245846056960
author Chhanda Das
Madhumita Mukhopadhyay
Satinath Mukhopadhyay
Avijit Hazra
author_facet Chhanda Das
Madhumita Mukhopadhyay
Satinath Mukhopadhyay
Avijit Hazra
author_sort Chhanda Das
collection DOAJ
description Background: Pituitary Adenoma, a neoplastic proliferation of anterior pituitary hormone producing cells, is mainly considered benign but some are clinically aggressive and recurrent and very rarely malignant. From recent advances in pathological and molecular study, there is a continuous search for numerous prognostic biomarkers, to analyze better tumor behavior and prediction of response to treatment and recurrences. This study was conducted to see the epidemiological spectrum of pituitary tumors and to evaluate the correlation of TOPOISOMERASE IIα (Topo 2A), and Ki-67 biomarker with recurrence, aggressiveness, hormone subtype, radiological invasiveness, and prognostic grade of pituitary tumors. Materials and methods:This was a prospective study with a total of 54 cases. We studied the clinical behavior, radiology, histopathological findings, and immunohistochemistry with Ki-67, Topoisomerase IIα, over 3 years at a tertiary care center. Results:When comparing Ki-67 expression with aggressiveness, a high degree of statistical significance was found (Mann -Whitney U Test, p-value <0.001 ). All of our aggressive tumors (8/54) had a Ki-67 level of≥3% while most of the nonaggressive tumors (46/54) had a Ki-67 level of <3%. When comparing Topo 2A expression with recurrence, a high degree of statistical significance was found (Mann Whitney U test, P value <0.001). Most of the recurrent tumor (11/15) had Topo 2A index of 1 % or more. Conclusions: The benign, aggressive, recurrence, or malignant nature of PA can be effectively predicted with the help of immunohistochemistry such as TOPO 2A and  Ki67, thereby guiding better patient management.
format Article
id doaj-art-98fad174d4044d91a3e412a74cd83c8d
institution Kabale University
issn 2091-0797
2091-0908
language English
publishDate 2023-12-01
publisher Association of Clinical Pathologists of Nepal
record_format Article
series Journal of Pathology of Nepal
spelling doaj-art-98fad174d4044d91a3e412a74cd83c8d2025-08-21T06:46:38ZengAssociation of Clinical Pathologists of NepalJournal of Pathology of Nepal2091-07972091-09082023-12-011322037204210.3126/jpn.v13i2.5101678084Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumorsChhanda Das0https://orcid.org/0000-0001-7859-875XMadhumita Mukhopadhyay1Satinath Mukhopadhyay2Avijit Hazra3Burdwan Medical CollegeIPGME&R, Kolkata, IndiaIPGME&R, Kolkata, IndiaIPGME&R, Kolkata, IndiaBackground: Pituitary Adenoma, a neoplastic proliferation of anterior pituitary hormone producing cells, is mainly considered benign but some are clinically aggressive and recurrent and very rarely malignant. From recent advances in pathological and molecular study, there is a continuous search for numerous prognostic biomarkers, to analyze better tumor behavior and prediction of response to treatment and recurrences. This study was conducted to see the epidemiological spectrum of pituitary tumors and to evaluate the correlation of TOPOISOMERASE IIα (Topo 2A), and Ki-67 biomarker with recurrence, aggressiveness, hormone subtype, radiological invasiveness, and prognostic grade of pituitary tumors. Materials and methods:This was a prospective study with a total of 54 cases. We studied the clinical behavior, radiology, histopathological findings, and immunohistochemistry with Ki-67, Topoisomerase IIα, over 3 years at a tertiary care center. Results:When comparing Ki-67 expression with aggressiveness, a high degree of statistical significance was found (Mann -Whitney U Test, p-value <0.001 ). All of our aggressive tumors (8/54) had a Ki-67 level of≥3% while most of the nonaggressive tumors (46/54) had a Ki-67 level of <3%. When comparing Topo 2A expression with recurrence, a high degree of statistical significance was found (Mann Whitney U test, P value <0.001). Most of the recurrent tumor (11/15) had Topo 2A index of 1 % or more. Conclusions: The benign, aggressive, recurrence, or malignant nature of PA can be effectively predicted with the help of immunohistochemistry such as TOPO 2A and  Ki67, thereby guiding better patient management.https://www.nepjol.info/index.php/JPN/article/view/51016immunohistochemistryki67pituitary adenomaprognosistopoisomerase iiα
spellingShingle Chhanda Das
Madhumita Mukhopadhyay
Satinath Mukhopadhyay
Avijit Hazra
Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
Journal of Pathology of Nepal
immunohistochemistry
ki67
pituitary adenoma
prognosis
topoisomerase iiα
title Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
title_full Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
title_fullStr Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
title_full_unstemmed Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
title_short Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
title_sort role of topoisomerase ii α and ki 67 biomarkers in pituitary tumors
topic immunohistochemistry
ki67
pituitary adenoma
prognosis
topoisomerase iiα
url https://www.nepjol.info/index.php/JPN/article/view/51016
work_keys_str_mv AT chhandadas roleoftopoisomeraseiiaandki67biomarkersinpituitarytumors
AT madhumitamukhopadhyay roleoftopoisomeraseiiaandki67biomarkersinpituitarytumors
AT satinathmukhopadhyay roleoftopoisomeraseiiaandki67biomarkersinpituitarytumors
AT avijithazra roleoftopoisomeraseiiaandki67biomarkersinpituitarytumors